XESMMLC
Market cap173mUSD
Jan 13, Last price
8.70EUR
1D
0.00%
1Q
45.00%
Jan 2017
-28.69%
IPO
-21.27%
Name
Malin Corporation PLC
Chart & Performance
Profile
Malin Corporation plc, through its subsidiaries, operates in the life sciences industry in Ireland and the United States. It offers life-saving cell and gene therapies for patients with high unmet medical need; medicines to address unmet needs in cancer, infection, and autoimmune diseases; and treatment of recurrent vulvovaginal candidiasis, an unmet need in women's health and onychomycosis or fungal nail infection. The company also provides drugs for protein misfolding diseases; and platform to distinguish disease-driving bacteria from the intestinal microbiota, as well as UV-light disinfection technology solutions. In addition, it provides company secretarial services. Malin Corporation plc was incorporated in 2014 and is headquartered in Dublin, Ireland.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | |||||||||
Cost of revenue | 3,900 | 200 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (3,900) | (200) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (600) | ||||||||
Tax Rate | |||||||||
NOPAT | (3,900) | 400 | |||||||
Net income | 12,900 -2,680.00% | ||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | (140,800) | ||||||||
BB yield | 140.31% | ||||||||
Debt | |||||||||
Debt current | 100 | 100 | |||||||
Long-term debt | 100 | 100 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | 6,100 | ||||||||
Net debt | (110,300) | (173,808) | |||||||
Cash flow | |||||||||
Cash from operating activities | (3,200) | (7,200) | |||||||
CAPEX | |||||||||
Cash from investing activities | 400 | 149,100 | |||||||
Cash from financing activities | (141,700) | (200) | |||||||
FCF | (3,900) | 400 | |||||||
Balance | |||||||||
Cash | 35,700 | 173,900 | |||||||
Long term investments | 74,800 | 108 | |||||||
Excess cash | 110,500 | 174,008 | |||||||
Stockholders' equity | 118,200 | 257,000 | |||||||
Invested Capital | 5,200 | 109,192 | |||||||
ROIC | 0.27% | ||||||||
ROCE | |||||||||
EV | |||||||||
Common stock shares outstanding | 22,300 | 34,300 | |||||||
Price | 4.50 -38.02% | 7.26 8.36% | |||||||
Market cap | 100,350 -59.70% | 249,018 -16.67% | |||||||
EV | (9,950) | 75,210 | |||||||
EBITDA | (3,700) | 100 | |||||||
EV/EBITDA | 2.69 | 752.10 | |||||||
Interest | 200 | ||||||||
Interest/NOPBT |